Dermatofibrosarcoma Protuberans

被引:53
|
作者
Acosta, Alvaro E. [1 ]
Santa Velez, Catalina [2 ]
机构
[1] Univ Nacl Colombia, Inst Nacl Cancerol, Dermatol Dept, Carrera 19C 90-14, Bogota, Colombia
[2] Univ Mil Nueva Granada, Inst Nacl Cancerol, Dermatol Oncol, Calle 1a 9-85, Bogota, Colombia
关键词
Dermatofibrosarcoma protuberans; Mohs micrographic surgery; Imatinib mesylate; Radiotherapy; Pathology; Surgery; MOHS MICROGRAPHIC SURGERY; WIDE LOCAL EXCISION; MULTICENTER PHASE-II; TERM-FOLLOW-UP; SURGICAL-TREATMENT; IMATINIB MESYLATE; THERAPY; OUTCOMES; MARGINS; DFSP;
D O I
10.1007/s11864-017-0498-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Dermatofibrosarcoma protuberans (DFSP) is a slow growing tumor with a very low metastatic potential but with significant subclinical extension and great capacity for local destruction. Thus, the first surgeon approached with such challenging tumor must attempt to cure the patient with a method that spares healthy tissue and ensures an optimal oncological, functional, and esthetic result. The treatment of DFSP often requires a multidisciplinary approach. Depending on location, dermatologic surgeons, surgical oncologists, head and neck surgeons, neurosurgeons, plastic surgeons, and occasionally medical oncologists may be involved with the management. Mohs micrographic surgery (MMS) is the preferred method when available. In our institution, most of the DFSP cases are often advanced cases; thus, dermatologic surgeons obtain clear margins peripherally and other surgical specialties assist with resection of the fascia and any critical deeper structures. When MMS is not available, wide local excision (at least 2- to 3-cm margins of resection) with exhaustive pathologic assessment of margin status is recommended, and it is best to confirm tumor extirpation prior to any reconstruction. Subclinical extension of the tumor could be related to the size; how long it has been growing or histological markers that are unknown right now. No clinical trials comparing MMS vs WLE are available, and further research should be focused on these subjects as well as the use of imatinib and other targeted therapies for recurrent and metastatic tumors and for neoadjuvant treatment.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Dermatofibrosarcoma protuberans
    Ugurel, S.
    HAUTARZT, 2008, 59 (11): : 933 - 939
  • [22] DERMATOFIBROSARCOMA PROTUBERANS
    PHELAN, JT
    JUARDO, J
    AMERICAN JOURNAL OF SURGERY, 1963, 106 (06): : 943 - 948
  • [23] Dermatofibrosarcoma Protuberans
    Alvaro E. Acosta
    Catalina Santa Vélez
    Current Treatment Options in Oncology, 2017, 18
  • [24] DERMATOFIBROSARCOMA PROTUBERANS
    BLOOM, D
    ARCHIVES OF DERMATOLOGY, 1955, 72 (02) : 202 - 203
  • [25] Dermatofibrosarcoma protuberans
    Gloster, HM
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 35 (03) : 355 - 374
  • [26] Dermatofibrosarcoma Protuberans
    LeBlanc, Jessica
    Chan, Conner
    Zedlitz, Ann
    CUTIS, 2017, 100 (01): : E6 - E7
  • [27] Dermatofibrosarcoma Protuberans
    Allen, Aubrey
    Ahn, Christine
    Sangueza, Omar P.
    DERMATOLOGIC CLINICS, 2019, 37 (04) : 483 - +
  • [28] Dermatofibrosarcoma protuberans
    Camilo Barrera, Juan
    Enrique Acosta, Alvaro
    Trujillo, Laura
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2019, 23 (03): : 99 - 109
  • [29] DERMATOFIBROSARCOMA PROTUBERANS
    WADDINGTON, E
    PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1954, 46 (11): : 906 - 907
  • [30] DERMATOFIBROSARCOMA PROTUBERANS
    MOPPER, C
    ARCHIVES OF DERMATOLOGY, 1957, 76 (02) : 258 - 258